MOVE: TGCT patient experience with vimseltinib
Part of Bones, joints & muscles, Cancer clinical trials.
This study is collecting real-world data from people with TGCT who have been prescribed vimseltinib. It is not testing the drug itself — it simply tracks your experience to help doctors understand how the treatment works outside of a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Tenosynovial Giant Cell Tumor (TGCT) — a type of tumor that grows in the lining of joints or tendons.
- You have already been prescribed vimseltinib by your doctor, or the decision to start vimseltinib has been made.
- You agree to sign consent forms and allow the study team to access your medical records.
- You are not currently taking part in another clinical trial that tests vimseltinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called pimicotinib for people in Japan with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. It aims to see if the drug can help with pain and stiffness caused by the tumor.
This trial tests a new drug called vimseltinib for people with active chronic graft versus host disease (cGVHD) that hasn't gotten better after at least two prior treatments. The goal is to see if vimseltinib can help control the condition.
This study is for healthy men to see how a new drug called vimseltinib affects a protein in your body that helps remove other drugs. Participation will help your doctors understand how to use this drug safely in the future.
This trial tests a new drug called velzatinib for people with advanced gastrointestinal stromal tumor (GIST) that has spread or cannot be removed by surgery. It is for those whose cancer has worsened after trying several standard treatments.
This trial tests whether taking pimicotinib before surgery improves outcomes for people with diffuse tenosynovial giant cell tumor (a non-cancerous growth in joints). You would receive the study drug for a while, then have surgery, and be compared to people who have surgery right away.
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
Hear when a new Tenosynovial Giant Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.